MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
OpGen Operating Income 2011-2026 | OPGN
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 325 K | -30.7 M | -34.6 M | -23.3 M | -22.7 M | -12.3 M | -13.2 M | -15.3 M | -19 M | -15.1 M | -5.56 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 325 K | -34.6 M | -17.4 M |
Quarterly Operating Income OpGen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -702 K | 3.4 M | -523 K | - | -784 K | -1.55 M | -1.75 M | - | -3.57 M | -5.16 M | -5.07 M | - | -13.5 M | -5.27 M | -5.85 M | - | -5.09 M | -6.14 M | -6.26 M | - | -6.18 M | -6.52 M | -3.99 M | - | -3.43 M | -2.58 M | -3.76 M | - | -3.23 M | -3.26 M | -3.02 M | - | -3.2 M | -4.19 M | -4.95 M | - | -4.81 M | -5.01 M | -4.48 M | - | -4.65 M | -3.05 M | -2.53 M | - | -1.58 M | -1.45 M | -1.19 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.4 M | -13.5 M | -3.75 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.35 B | $ 114.84 | -0.55 % | $ 34.9 B |  USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.3 | 0.62 % | $ 175 M |  China |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 15.36 | 1.92 % | $ 1.99 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 27.2 | 0.33 % | $ 20 B |  Niderland |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 17.82 | -2.68 % | $ 950 M | USA |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.59 | 1.57 % | $ 84.1 K | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.17 | - | $ 4.98 M | USA |
 |
BioNano Genomics
BNGO
|
-33.3 M | $ 1.15 | -4.17 % | $ 6.26 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 168.22 | -3.26 % | $ 8.34 B | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 24.73 | -0.44 % | $ 687 M | USA |
 |
Celcuity
CELC
|
-172 M | $ 114.22 | 1.41 % | $ 5.34 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 192.12 | 0.53 % | $ 137 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
912 M | $ 63.21 | 1.59 % | $ 24.7 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 198.96 | 0.91 % | $ 22.1 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 16.42 | -2.38 % | $ 496 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 89.66 | -4.44 % | $ 11.2 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 109.62 | -4.0 % | $ 9.04 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.97 | 0.63 % | $ 8.72 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 127.74 | 0.28 % | $ 20.3 B | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 170.72 | -1.47 % | $ 29.3 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 274.46 | 0.27 % | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 75.89 | -0.28 % | $ 5.12 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 496.0 | -0.47 % | $ 14.3 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.67 | -1.68 % | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-5.76 M | $ 4.74 | 1.07 % | $ 3.73 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 8.02 | 0.25 % | $ 1.03 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.56 | 1.59 % | $ 2.07 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.33 | 0.99 % | $ 388 M | USA |